Announcement on Change of Securities Affairs Representative
Filed with SSE · · 3 pages · Chinese
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhangzhou Pientzehuang Pharmaceutical
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Receiving the "Imported Medicinal Materials Approval Document"
- Announcement on External Investment through Participation in the Establishment of a Private Fund
- Announcement on Election of Employee Directors for the 7th Board of Directors
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
Later from Zhangzhou Pientzehuang Pharmaceutical
- Announcement on Completion of Implementation of Controlling Shareholder's Share Increase Plan and Results
- Announcement on Progress in Investing in the Regenerative Medicine Fund
- Notice on Convening the 2025 Annual General Meeting
- Announcement on Completion of First Participant Enrollment in the Phase III Clinical Trial of Changji’an Capsules
- Announcement on Resolutions of the 2025 Annual General Meeting
Follow Zhangzhou Pientzehuang Pharmaceutical into a list and get an email when it puts out news.
Follow Zhangzhou Pientzehuang Pharmaceutical